STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Versant Ventures, Eli Lilly, and a handful of other investors announced Monday that they have poured $100 million into a new startup devoted to solving a gene therapy challenge that has ensnared many well-funded academics and biotechs before it.
- The company, called Seawolf Therapeutics, is trying to deliver genes to patients without the use of viruses.
- Continue to STAT+ to read the full story….
- A patient can only ever receive a single dose, after which they develop antibodies against the virus.
In addition to the $100 million fundraising, Sanofi has also inked a partnership with the company.
Viruses have proven to be powerful gene delivery drones in several rare diseases, and they are being tested in hundreds of trials.
- And at high doses the treatments can have serious side effects.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →